Skip to main content
SpringerLink
Log in

Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension

  • Adis Drug Evaluation
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Tafluprost ophthalmic solution 0.0015 % preserved with benzalkonium chloride (BAK) 0.001 % is available in several Asian countries, including Japan. In pivotal trials, BAK-preserved tafluprost ophthalmic solution 0.0015 % lowered intraocular pressure (IOP) more effectively than placebo in Asian patients with normal-tension glaucoma and was at least as effective as latanoprost ophthalmic solution 0.005 % in Asian patients with primary open-angle glaucoma or ocular hypertension. In other prospective studies in Asian patients with glaucoma or ocular hypertension, tafluprost ophthalmic solution 0.0015 % was at least as effective as latanoprost ophthalmic solution 0.005 % or travoprost ophthalmic solution 0.004 % in terms of IOP lowering, and was considered easier to use and/or store. The efficacy of tafluprost ophthalmic solution 0.0015 % was maintained in the longer term. Tafluprost ophthalmic solution 0.0015 % was generally well tolerated. In conclusion, BAK-preserved tafluprost ophthalmic solution 0.0015 % remains a useful option for the treatment of Asian patients with glaucoma and ocular hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. European Glaucoma Society. Terminology and guidelines for glaucoma. 2014. http://www.eugs.org. Accessed 3 Mar 2016.

  2. Prum BE, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma: preferred practice pattern. Ophthalmology. 2016;123(1):P41–111.

    Article  PubMed  Google Scholar 

  3. Japan Glaucoma Society. Guidelines for glaucoma (2nd edition). 2006. http://www.ryokunaisho.jp/english/Guidelines_for_Glaucoma.pdf. Accessed 7 Mar 2016.

  4. Song BJ, Caprioli J. New directions in the treatment of normal tension glaucoma. Indian J Ophthalmol. 2014;62(5):529–37.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641–8.

    PubMed  Google Scholar 

  6. Irkec M, Bozkurt B, Mocan MC. Are preservatives necessary to improve efficacy of some glaucoma drops? Br J Ophthalmol. 2013;97(12):1493–4.

    Article  PubMed  Google Scholar 

  7. Ayaki M, Iwasawa A, Niwano Y. Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops. Biocontrol Sci. 2012;17(3):121–8.

    Article  CAS  PubMed  Google Scholar 

  8. Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol (Copenh). 2008;86(Suppl 242):14–9.

    Article  Google Scholar 

  9. Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78(4):767–76.

    Article  CAS  PubMed  Google Scholar 

  10. Santen UK Ltd. Saflutan (tafluprost) 15 micrograms/ml eye drops, solution: UK summary of product characteristics. 2015. http://www.medicines.org.uk/emc/. Accessed 4 Mar 2016.

  11. Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther. 2008;46(8):400–6.

    Article  CAS  PubMed  Google Scholar 

  12. Mochizuki H, Itakura H, Yokoyama T, et al. Twenty-four-hour ocular hypotensive effects of 0.0015 % tafluprost and 0.005 % latanoprost in healthy subjects. Jpn J Ophthalmol. 2010;54(4):286–90.

    Article  CAS  PubMed  Google Scholar 

  13. Traverso CE, Ropo A, Papadia M, et al. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010;26(1):97–104.

    Article  CAS  PubMed  Google Scholar 

  14. Fukano Y, Odani-Kawabata N, Nakamura M, et al. Intraocular penetration and intraocular pressure-lowering effect of new formulation 0.0015 % tafluprost ophthalmic solution with reduced benzalkonium chloride [in Japanese]. Atarashii Ganka. 2010;27(5):691–4.

    CAS  Google Scholar 

  15. Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837–45.

    Article  CAS  PubMed  Google Scholar 

  16. Asada H, Takaoka-Shichijo Y, Nakamura M, et al. Optimization of benzalkonium chloride concentration in 0.0015 % tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy [in Japanese]. Yakugaku Zasshi. 2010;130(6):867–71.

    Article  CAS  PubMed  Google Scholar 

  17. Nakagawa S, Usui T, Yokoo S, et al. Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Invest Ophthalmol Vis Sci. 2012;53(9):5154–60.

    Article  CAS  PubMed  Google Scholar 

  18. Kim EJ, Kim Y-H, Kang SH, et al. In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells. Korean J Ophthalmol. 2013;27(6):446–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chang C, Zhang AQ, Kagan DB, et al. Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost. Clin Exp Ophthalmol. 2015;43(2):164–72.

    Article  Google Scholar 

  20. Akaishi T, Kurashima H, Odani-Kawabata N, et al. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J Ocul Pharmacol Ther. 2010;26(2):181–6.

    Article  CAS  PubMed  Google Scholar 

  21. Kurashima H, Watabe H, Sato N, et al. Effects of prostaglandin F2α analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp Eye Res. 2010;91(6):853–9.

    Article  CAS  PubMed  Google Scholar 

  22. Giannico AT, Lima L, Shaw GC, et al. Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits. Arq Bras Oftalmol. 2016;79(1):33–6.

    Article  PubMed  Google Scholar 

  23. Ishigaki J, Miyake S, Harino S, et al. Effect of tafluprost on choroidal blood flow in glaucoma [in Japanese]. Atarashii Ganka. 2010;27(8):1115–8.

    Google Scholar 

  24. Sugiyama T, Shibata M, Kojima S, et al. Changes in microcirculation in the optic nerve head following topical tafluprost treatment in eyes with primary open-angle glaucoma [in Japanese]. Rinsho Ganka. 2011;65(4):475–9.

    Google Scholar 

  25. Shibata M, Sugiyama T, Kojima S, et al. Effects on visual field, morphology and microcirculation of optic nerve head following tafluprost treatment for 3 years in patients with glaucoma [in Japanese]. Rinsho Ganka. 2015;69(5):741–7.

    Google Scholar 

  26. Santen Pharmaceutical Co Ltd. Tapros® (tafluprost) ophthalmic solution 0.0015 %: Japanese prescribing information. 2015.

  27. Kuwayama Y, Komemushi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study [in Japanese]. Nip GG Zass. 2010;114(5):436–43.

    Google Scholar 

  28. Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015 % DE-085 (tafluprost) ophthalmic solution as compared to 0.005 % latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension [in Japanese]. Atarashii Ganka. 2008;25(11):1595–602.

    Google Scholar 

  29. Eguro T, Shoji N, Kasahara M, et al. A parallel-group comparison of hypotensive effect of latanoprost and tafluprost [in Japanese]. Rinsho Ganka. 2012;66(6):913–6.

    Google Scholar 

  30. Adachi M. Ocular hypotensive effect after switching from topical latanoprost to tafluprost [in Japanese]. Rinsho Ganka. 2011;65(1):85–9.

    Google Scholar 

  31. Kozaki J, Unoki K, Adachi M, et al. Efficacy of switching from latanoprost to tafluprost in patients with normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2010;27(6):827–30.

    Google Scholar 

  32. Nakamuro T, Nakano S, Kiyosaki K, et al. Comparison of efficacy and safety of tafluprost and latanoprost in patients with normal tension glaucoma [in Japanese]. Atarashii Ganka. 2013;30(1):113–6.

    Google Scholar 

  33. Takeda S, Koyama H, Matsubara M. Efficacy of switching from latanoprost to tafluprost for glaucoma [in Japanese]. Rinsho Ganka. 2010;64(10):1685–9.

    Google Scholar 

  34. Mizoguchi T, Ozaki M, Unoki K, et al. A randomized crossover study comparing tafluprost 0.0015 % with travoprost 0.004 % in patients with normal-tension glaucoma. Clin Ophthalmol. 2012;6:1579–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Nakano S, Kubota T. Long-term efficacy of tafluprost after switching from latanoprost [in Japanese]. Atarashii Ganka. 2010;27(12):1727–30.

    Google Scholar 

  36. Sone A, Katsushima H, Funahashi K, et al. Efficacy and safety of 0.0015 % tafluprost ophthalmic solution in normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2011;28(4):568–70.

    Google Scholar 

  37. Nakano T, Yoshikawa K, Kimura T, et al. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn J Ophthalmol. 2011;55(6):605–13.

    Article  CAS  PubMed  Google Scholar 

  38. Miyagawa Y, Yamazaki H, Nakazawa M. Short-term efficacy of tafluprost monotherapy for untreated glaucoma [in Japanese]. Atarashii Ganka. 2010;27(7):967–9.

    Google Scholar 

  39. Kuwayama Y, Nomura A. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther. 2014;31(4):461–71.

    Article  CAS  PubMed  Google Scholar 

  40. Okada F, Inoue K, Wakakura M, et al. Ocular hypotensive effects and safety of tafluprost in normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2011;28(7):1043–6.

    Google Scholar 

  41. Watanabe S, Kimura I, Nakazawa Y, et al. The investigation of the clinical results of tafluprost in normal-tension glaucoma [in Japanese]. Folia Japonica de Ophthalmologica Clinica. 2014;7(8):597–602.

    Google Scholar 

  42. Nakauchi T, Okami T, Yamagishi K. Long-term intraocular pressure-lowering effect of tafluprost in patients with normal-tension glaucoma [in Japanese]. Atarashii Ganka. 2011;28(8):1161–5.

    Google Scholar 

  43. Inoue K, Tanaka A, Tomita G. Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol. 2013;7:1411–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ge J, Li X, Sun X. Randomized parallel group study of 0.0015 % tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005 % latanoprost ophthalmic solution) [in Chinese]. Zhonghua Yan Ke Za Zhi. 2015;51(2):95–102.

    PubMed  Google Scholar 

  45. Tanabe Y, Kanno M, Yamashita H. Intraocular pressure-lowering effect of travoprost, tafluprost and bimatoprost in normal tension glaucoma [in Japanese]. Atarashii Ganka. 2012;29(8):1131–5.

    Google Scholar 

  46. Inoue K, Masumoto M, Wakakura M, et al. Ocular hypotensive effects of latanoprost, travoprost and tafluprost [in Japanese]. Atarashii Ganka. 2010;27(3):383–6.

    Google Scholar 

  47. Inoue K, Setogawa A, Tomita G. Nonresponders to prostaglandin analogs among normal-tension glaucoma patients. J Ocul Pharmacol Ther. 2016;32(2):90–6.

    Article  CAS  PubMed  Google Scholar 

  48. Yoshida S. Adherence to topical tafluprost treatment for one year in glaucoma patients [in Japanese]. Rinsho Ganka. 2012;66(3):287–9.

    Google Scholar 

  49. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015 % versus latanoprost 0.005 % eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88(1):12–9.

    Article  CAS  PubMed  Google Scholar 

  50. Yoshino T, Fukuchi T, Togano T, et al. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol. 2013;57(2):172–8.

    Article  CAS  PubMed  Google Scholar 

  51. Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (London, England). 2012;26(11):1465–72.

    Article  CAS  Google Scholar 

  52. Inoue K, Shiokawa M, Wakakura M, et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626–31.

    Article  PubMed  Google Scholar 

  53. Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58(2):212–7.

    Article  CAS  PubMed  Google Scholar 

  54. Kumagami T, Wakiyama H, Kusano M, et al. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther. 2014;30(4):340–5.

    Article  CAS  PubMed  Google Scholar 

  55. Suzuki K, Teranishi S, Sagara T, et al. Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial punctate keratitis. J Glaucoma. 2015;24(6):e145–50.

    Article  PubMed  Google Scholar 

  56. Kanamoto T, Kiuchi Y, Tanito M, et al. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and sofZia-preserved travoprost applied to the ocular surface. J Ocul Pharmacol Ther. 2015;31(3):156–64.

    Article  CAS  PubMed  Google Scholar 

  57. Nakamura T, Kanamoto T, Komatsu N, et al. Satisfaction and subjective symptoms after instillation of tafluprost or travoprost for twelve weeks each [in Japanese]. Rinsho Ganka. 2014;68(7):959–66.

    Google Scholar 

  58. Ermiş SS. Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma. Clin Ophthalmol. 2012;6:673–8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

During the peer review process, the manufacturer of tafluprost ophthalmic solution 0.0015 % was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Gillian M. Keating

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Gillian Keating is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: Y. Kuwayama, Fukushima Eye Clinic, Osaka, Japan; M. Ozaki, Ozaki Eye Hospital and Department of Ophthalmology, University of Miyazaki, Miyazaki, Japan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keating, G.M. Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension. Clin Drug Investig 36, 499–508 (2016). https://doi.org/10.1007/s40261-016-0413-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-016-0413-z

Keywords

Search

Navigation